Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 2/20 | 0.69 |
| ▸ | IGF1R | P08069 | 2/20 | 0.69 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.65 |
| ▸ | MYC | P01106 | 1/20 | 0.62 |
| ▸ | MAX | P61244 | 1/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622882 | 1.00 | INSR (0.69) | INSRIGF1RPTP4A3MYCMAX | |
| SCHEMBL622884 | 1.00 | INSR (0.69) | INSRIGF1RPTP4A3MYCMAX | |
| SCHEMBL15313049 | 0.87 | GSK3B (0.70) | INSRIGF1RTNFRSF1APIK3CGPIK3CA | |
| SCHEMBL10118549 | 0.87 | GSK3B (0.70) | INSRIGF1RTNFRSF1APIK3CGPIK3CA | |
| SCHEMBL622799 | 0.84 | PIK3CG (0.80) | INSRIGF1RPTP4A3PIM1PIK3CG | |
| SCHEMBL622800 | 0.84 | PIK3CG (0.80) | INSRIGF1RPTP4A3PIM1PIK3CG | |
| SCHEMBL622801 | 0.84 | PIK3CG (0.80) | INSRIGF1RPTP4A3PIM1PIK3CG | |
| SCHEMBL6090645 | 0.82 | IGF1R (0.74) | INSRIGF1RPTP4A3PIM1PIK3CG | |
| SCHEMBL6090652 | 0.82 | IGF1R (0.74) | INSRIGF1RPTP4A3PIM1PIK3CG | |
| SCHEMBL623774 | 0.82 | IGF1R (1.00) | INSRIGF1RPTP4A3PIM1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | INSR 4125/4885IGF1R 4789/4885PTP4A3 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.